[go: up one dir, main page]

SI1175408T1 - Pyrimidinone compounds - Google Patents

Pyrimidinone compounds

Info

Publication number
SI1175408T1
SI1175408T1 SI200030609T SI200030609T SI1175408T1 SI 1175408 T1 SI1175408 T1 SI 1175408T1 SI 200030609 T SI200030609 T SI 200030609T SI 200030609 T SI200030609 T SI 200030609T SI 1175408 T1 SI1175408 T1 SI 1175408T1
Authority
SI
Slovenia
Prior art keywords
pyrimidinone compounds
pyrimidinone
compounds
Prior art date
Application number
SI200030609T
Other languages
English (en)
Slovenian (sl)
Inventor
Ashley Edward SmithKline Beecham Pharma. FENWICK
Deirdre M. B. SmithKline Beecham Pharma. HICKEY
Robert John SmithKline Beecham Pharma. IFE
Colin Andrew SmithKline Beecham Pharma. LEACH
Ivan Leo SmithKline Beecham Pharma. PINTO
Stephen Allan SmithKline Beecham Pharma. SMITH
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9910048A external-priority patent/GB9910048D0/en
Priority claimed from GB0002096A external-priority patent/GB0002096D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of SI1175408T1 publication Critical patent/SI1175408T1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/56—One oxygen atom and one sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SI200030609T 1999-05-01 2000-04-25 Pyrimidinone compounds SI1175408T1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9910048A GB9910048D0 (en) 1999-05-01 1999-05-01 Novel compounds
GB0002096A GB0002096D0 (en) 2000-01-28 2000-01-28 Novel compounds
PCT/EP2000/003727 WO2000066567A1 (fr) 1999-05-01 2000-04-25 Composes pyrimidinones
EP00920741A EP1175408B1 (fr) 1999-05-01 2000-04-25 Composes pyrimidinones

Publications (1)

Publication Number Publication Date
SI1175408T1 true SI1175408T1 (en) 2005-04-30

Family

ID=26243514

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200030609T SI1175408T1 (en) 1999-05-01 2000-04-25 Pyrimidinone compounds

Country Status (29)

Country Link
US (2) US6953803B1 (fr)
EP (2) EP1479671B1 (fr)
JP (1) JP2002543190A (fr)
KR (1) KR20020012200A (fr)
CN (1) CN1286822C (fr)
AR (1) AR023777A1 (fr)
AT (2) ATE283845T1 (fr)
AU (1) AU766003B2 (fr)
BR (1) BR0010220A (fr)
CA (1) CA2371671A1 (fr)
CO (1) CO5170521A1 (fr)
CZ (1) CZ20013904A3 (fr)
DE (2) DE60042286D1 (fr)
DK (1) DK1175408T3 (fr)
ES (1) ES2233361T3 (fr)
HK (1) HK1044757B (fr)
HU (1) HUP0201122A3 (fr)
IL (1) IL146210A0 (fr)
MX (1) MXPA01011186A (fr)
MY (1) MY136037A (fr)
NO (1) NO20015329D0 (fr)
NZ (1) NZ515137A (fr)
PE (1) PE20010070A1 (fr)
PL (1) PL351690A1 (fr)
PT (1) PT1175408E (fr)
SI (1) SI1175408T1 (fr)
TR (1) TR200103216T2 (fr)
UY (1) UY26132A1 (fr)
WO (1) WO2000066567A1 (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1175408E (pt) * 1999-05-01 2005-04-29 Smithkline Beecham Plc Derivados sulfonamida
ATE437862T1 (de) 2000-02-16 2009-08-15 Smithkline Beecham Plc Pyrimidin-5-onderivate als ldl-pla2 inhibitoren
GB0024808D0 (en) 2000-10-10 2000-11-22 Smithkline Beecham Plc Novel compounds
GB0119793D0 (en) * 2001-08-14 2001-10-03 Smithkline Beecham Plc Novel compounds
GB0127143D0 (en) * 2001-11-10 2002-01-02 Smithkline Beecham Novel compounds
GB0127139D0 (en) * 2001-11-10 2002-01-02 Smithkline Beecham Novel compounds
GB0208280D0 (en) * 2002-04-10 2002-05-22 Glaxo Group Ltd Novel compounds
CA2530816A1 (fr) * 2003-07-02 2005-01-13 Bayer Healthcare Ag 1,2,4-triazino-5(2h)-ones a substitution amide destinees au traitement de maladies inflammatoires chroniques
WO2005113797A2 (fr) 2004-04-16 2005-12-01 Glaxo Group Limited PROCÉDÉS SERVANT À DÉTECTER L'ACTIVITÉ DE LA Lp-PLA2 ET L'INHIBITION DE L'ACTIVITÉ DE LA Lp-PLA2
US20150017671A1 (en) 2004-04-16 2015-01-15 Yaping Shou Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity
DE102004061009A1 (de) * 2004-12-18 2006-06-22 Bayer Healthcare Ag Substituierte 1,2,4-Triazin-5(2H)-one
DE102004061006A1 (de) * 2004-12-18 2006-06-22 Bayer Healthcare Ag 3-Benzylthio-1,2,4-triazin-5(2H)-one
CN1954826A (zh) * 2005-10-26 2007-05-02 上海生物芯片有限公司 银杏叶提取物在降低胆固醇方面的用途
CN101986785A (zh) 2007-05-11 2011-03-16 托马斯杰弗逊大学 治疗和预防神经退行性疾病和紊乱的方法
MX2009012197A (es) 2007-05-11 2010-01-15 Univ Pennsylvania Metodos para tratamiento de ulceras en la piel.
AR081399A1 (es) * 2010-05-17 2012-08-29 Glaxo Group Ltd Proceso para preparar un compuesto de pirimidinona, compuestos intermediarios en dicho proceso y procesos para repararlos.
CN104478812A (zh) * 2010-12-06 2015-04-01 葛兰素集团有限公司 用于治疗由Lp-PLA2介导的疾病或病症的嘧啶酮化合物
JP5886310B2 (ja) 2010-12-06 2016-03-16 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ Ｌｐ−ＰＬＡ２により媒介される疾患または状態の処置における使用のためのピリミジノン化合物
EP2651403B1 (fr) 2010-12-17 2020-12-02 Glaxo Group Limited Procédés de traitement et de prévention de maladies oculaires
WO2013000108A1 (fr) * 2011-06-27 2013-01-03 中国科学院上海药物研究所 Composés hétérocycliques azoles, procédés de préparation, compositions pharmaceutiques et leurs utilisations
JP2014521625A (ja) 2011-07-27 2014-08-28 グラクソ グループ リミテッド 二環式ピリミドン化合物
US8975400B2 (en) 2011-07-27 2015-03-10 Glaxo Group Limited 2,3-dihydroimidazo[1, 2-c] pyrimidin-5(1 H)-one compounds use as LP-PLA2 inhibitors
MX351299B (es) * 2011-11-11 2017-10-10 Pfizer 2-tiopirimidinonas.
AU2014210259B2 (en) 2013-01-25 2016-11-03 Glaxosmithkline Intellectual Property Development Limited Compounds
ES2642762T3 (es) 2013-01-25 2017-11-20 Glaxosmithkline Intellectual Property Development Limited Inhibidores de fosfolipasa A2 asociada a lipoproteínas (LP-PLA2) basados en 2,3-dihidroimidazol[1,2-c]pirimidin-5(1H)-ona
EP2948456A4 (fr) 2013-01-25 2016-09-14 Glaxosmithkline Ip Dev Ltd Composés de pyrimidone bicycliques utilisés en tant qu'inhibiteurs de lp-pla2
US20140283157A1 (en) 2013-03-15 2014-09-18 Diadexus, Inc. Lipoprotein-associated phospholipase a2 antibody compositions and methods of use
US9552473B2 (en) 2014-05-14 2017-01-24 Microsoft Technology Licensing, Llc Claiming data from a virtual whiteboard
WO2016012917A1 (fr) 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited Dérivés 1,2,3,5-tétrahydro-imidazo [1,2-c]pyrimidine utiles pour le traitement de maladies et de troubles médiés par la lp-pla2
WO2016012916A1 (fr) 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited Dérivés 1,2,3,5-tétrahydro-imidazo [1,2-c]pyrimidine utiles pour le traitement de maladies et de troubles médiés par la lp-pla2
CN104840963B (zh) * 2015-05-26 2018-02-16 河北东康生物科技有限公司 含脂蛋白相关性磷脂酶a2抑制剂的药物组合物及应用
CN106008362B (zh) * 2016-05-24 2018-08-10 杰达维（上海）医药科技发展有限公司 一种嘧啶衍生物的制备方法
JP6545747B2 (ja) * 2017-05-09 2019-07-17 山田化学工業株式会社 色素化合物
MX2022005615A (es) 2019-11-09 2022-07-27 Shanghai Simr Biotechnology Co Ltd Derivado triciclico de dihidroimidazopirimidona, metodo de preparacion del mismo, composicion farmaceutica y uso del mismo.
CN115304620A (zh) 2021-05-07 2022-11-08 上海赛默罗生物科技有限公司 嘧啶酮衍生物、其制备方法、药物组合物和用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1582527A (en) * 1975-12-29 1981-01-07 Smith Kline French Lab Pyrimidone and thiopyrimidone derivatives
JP2001522844A (ja) * 1997-11-06 2001-11-20 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー ピリミジノン化合物およびそれを含有する医薬組成物
ATE251613T1 (de) * 1998-08-21 2003-10-15 Smithkline Beecham Plc Pyrimidinonderivate zur behandlung von atheroscleros
PT1175408E (pt) * 1999-05-01 2005-04-29 Smithkline Beecham Plc Derivados sulfonamida

Also Published As

Publication number Publication date
DK1175408T3 (da) 2005-04-11
DE60016397D1 (de) 2005-01-05
ES2233361T3 (es) 2005-06-16
NO20015329L (no) 2001-10-31
MY136037A (en) 2008-08-29
HK1044757A1 (en) 2002-11-01
KR20020012200A (ko) 2002-02-15
US20040167142A1 (en) 2004-08-26
WO2000066567A1 (fr) 2000-11-09
US6953803B1 (en) 2005-10-11
AU766003B2 (en) 2003-10-09
HK1044757B (en) 2005-07-08
CA2371671A1 (fr) 2000-11-09
HUP0201122A2 (en) 2002-08-28
HUP0201122A3 (en) 2003-11-28
BR0010220A (pt) 2002-05-14
CO5170521A1 (es) 2002-06-27
NZ515137A (en) 2003-10-31
EP1175408A1 (fr) 2002-01-30
EP1479671B1 (fr) 2009-05-27
TR200103216T2 (tr) 2002-04-22
AR023777A1 (es) 2002-09-04
NO20015329D0 (no) 2001-10-31
UY26132A1 (es) 2000-12-29
PT1175408E (pt) 2005-04-29
CZ20013904A3 (cs) 2002-04-17
IL146210A0 (en) 2002-07-25
CN1358175A (zh) 2002-07-10
PL351690A1 (en) 2003-06-02
CN1286822C (zh) 2006-11-29
MXPA01011186A (es) 2002-08-12
JP2002543190A (ja) 2002-12-17
DE60016397T2 (de) 2005-12-01
DE60042286D1 (de) 2009-07-09
EP1175408B1 (fr) 2004-12-01
ATE432265T1 (de) 2009-06-15
AU4120300A (en) 2000-11-17
US7115616B2 (en) 2006-10-03
ATE283845T1 (de) 2004-12-15
EP1479671A1 (fr) 2004-11-24
PE20010070A1 (es) 2001-03-10

Similar Documents

Publication Publication Date Title
IL146210A0 (en) Pyrimidinone compounds
GB2357761B (en) Compounds
GB9904933D0 (en) Compounds
GB9904930D0 (en) Thiazoloindolinone compounds
GB9902399D0 (en) Compounds
GB9908828D0 (en) Compounds
GB9914821D0 (en) Compounds
GB9905771D0 (en) Compounds
GB9916647D0 (en) Compounds
ZA200108991B (en) Pyrimidinone compounds.
GB9903287D0 (en) Compounds
GB9903271D0 (en) Compounds
GB9903239D0 (en) Compounds
GB9903241D0 (en) Compounds
GB9903243D0 (en) Compounds
GB9903266D0 (en) Compounds
GB9903268D0 (en) Compounds
GB9903269D0 (en) Compounds
GB9906278D0 (en) Compounds
GB9903272D0 (en) Compounds
GB9903273D0 (en) Compounds
GB9903280D0 (en) Compounds
GB9901429D0 (en) Compounds
GB9903288D0 (en) Compounds
GB9903290D0 (en) Compounds